Low-Dose Naltrexone for Chronic Pain in Personal Injury Cases: Attorney Guide

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | February 17, 2026 | 8 min read

Low-dose naltrexone (LDN) is an emerging off-label treatment for chronic neuropathic and inflammatory pain — prescribed for fibromyalgia, CRPS, and post-traumatic pain syndromes. Its presence in a PI client's pharmacy record signals a chronic pain trajectory that supports high-value case development.

What Is Low-Dose Naltrexone?

Naltrexone is an opioid receptor antagonist FDA-approved at 50 mg/day for opioid and alcohol use disorder. At much lower doses — typically 1.5 to 4.5 mg/day — it has a fundamentally different mechanism that has attracted significant research interest for chronic pain and inflammatory conditions.

This off-label use is known as low-dose naltrexone (LDN). At standard blocking doses, naltrexone competitively binds and blocks opioid receptors. At low doses, it transiently blocks these receptors for a short period, triggering a compensatory upregulation of endogenous opioid production — the "rebound effect." This increased endorphin production appears to have analgesic and anti-inflammatory effects that persist beyond the drug's blocking activity.

Additionally, LDN at these doses appears to modulate glial cell activity — specifically microglia and astrocytes — reducing neuroinflammation that contributes to central sensitization and chronic pain maintenance. This mechanism is separate from its opioid receptor effects.

LDN is exclusively available through compounding pharmacies — there is no FDA-approved naltrexone product at 1.5–4.5 mg doses. Prescriptions must be compounded, usually as an oral capsule.

[!KEY] An LDN prescription in a PI client's pharmacy record signals that the treating physician has identified a chronic pain syndrome — not acute pain — that requires ongoing pharmacological management targeting neuroinflammation and central sensitization. This is the language of complex, long-duration, high-value cases.

When Is LDN Prescribed After a PI Injury?

LDN is not a first-line or acute pain medication. It is prescribed when:

1. Standard pain management has proven inadequate: NSAIDs, muscle relaxants, and short-course opioids have not provided sufficient relief
2. A chronic pain syndrome has emerged: CRPS (Complex Regional Pain Syndrome), fibromyalgia, post-traumatic pain syndrome, or central sensitization has been diagnosed or suspected
3. The treating physician is pursuing a non-opioid chronic pain strategy: LDN is increasingly preferred over long-term opioid therapy for centrally-mediated chronic pain — it carries no addiction potential, no DEA scheduling, and no tolerance development

Common PI diagnoses driving LDN prescribing:

• CRPS Type I/II (RSD): LDN appears in a subset of CRPS treatment protocols, particularly when patients are opioid-intolerant or seeking to avoid long-term opioid dependence
• Fibromyalgia following trauma: Post-traumatic fibromyalgia is a recognized sequela of significant accidents; LDN has RCT evidence in primary fibromyalgia
• Post-traumatic central sensitization: When chronic widespread pain emerges after a traumatic injury, LDN targets the glial-mediated neuroinflammation underlying the sensitized state
• Inflammatory conditions aggravated by trauma: Some post-traumatic inflammatory arthropathies respond to LDN's anti-inflammatory mechanisms

The Evidence Base for LDN

The evidence for LDN in chronic pain is developing but meaningful for PI purposes:

Fibromyalgia: A randomized, double-blind, placebo-controlled crossover trial at Stanford University (Younger & Mackey, 2009) found significant reductions in fibromyalgia pain scores with LDN compared to placebo, with the effect attributed to microglial modulation.

Multiple Sclerosis pain: LDN has the most evidence in MS-related pain — not directly a PI indication, but establishing the glial-modulation mechanism that applies broadly to neuroinflammatory pain states.

CRPS: Small case series and observational data support LDN use in CRPS, particularly in patients who have exhausted standard pharmacological options.

FDA approval status: LDN is not FDA-approved for any chronic pain indication. All use is off-label. Compounded LDN requires physician prescription and pharmacy compounding.

[!NOTE] The off-label status of LDN does not undermine its value in the PI pharmacy record. When a board-certified pain management physician or rheumatologist prescribes LDN for a PI client's post-traumatic pain syndrome, that prescription represents a clinical judgment that the condition warrants a specialized, ongoing treatment intervention. Defense counsel who challenge the prescription as "unproven" should be directed to the peer-reviewed evidence and the treating physician's expertise.

[!KEY] Because LDN is exclusively available through compounding pharmacies, standard health insurance almost never covers it — making pharmacy lien access the primary mechanism through which PI clients can fill LDN prescriptions at $0 upfront. Without a lien program, clients with post-traumatic chronic pain syndromes often simply go without this treatment.

LDN in the PI Demand Package

Economic damages:

LDN is typically moderately priced as a compounded medication — not as expensive as biologic infusions or ketamine, but meaningful as a line item when filled monthly over a long treatment period. Every month of LDN fills represents a month of documented, treated chronic pain.

Non-economic damages narrative:

The prescribing narrative around LDN is powerful. A physician who prescribes LDN is communicating:

• Acute pain medications have been tried and found insufficient
• The patient has a chronic pain syndrome — not a temporary injury
• The physician is using a targeted anti-neuroinflammatory approach to manage central sensitization
• The expectation is long-term treatment, not a short course

In the demand letter, LDN prescribing supports an argument for ongoing future medical expenses — the physician's LDN strategy is not a finite treatment course, it is chronic pain management.

Future medical expense projection:

If LDN is ongoing at the time of settlement, the future prescription cost is projectable. A Life Care Planner (LCP) or economist can calculate the present value of monthly LDN compounding costs over the plaintiff's projected life expectancy. This future cost component is a significant addition to economic damages in chronic pain cases.

[!KEY] When LDN is ongoing at the time of settlement, its monthly cost is projectable over the plaintiff's life expectancy — a future medical expense that a Life Care Planner can calculate and include in the economic damages demand. A single LDN prescription can justify a significant future-expense calculation in the right case.

Pharmacy Lien Coverage for LDN

Because LDN is a compounded medication, it may not be covered by standard health insurance (most health plans exclude compounded medications). For PI clients accessing chronic pain treatment through a pharmacy lien program, LDN dispensed by a compounding pharmacy can be enrolled in the lien program:

• $0 upfront to the patient
• Complete pharmaceutical documentation in the POGOS
• Lien resolves from PI settlement proceeds

LienScripts' compounding pharmacy network can fulfill LDN prescriptions, ensuring that clients accessing this emerging treatment can do so without out-of-pocket cost during the pendency of their PI claim.

Related Resources

• Ketamine for CRPS in Personal Injury Cases
• CRPS and Pharmacy Lien Coverage
• Pharmacy Lien Support for Pain Management Doctors
• What Is a POGOS Report?
• Pharmacy Services for Personal Injury Clients

[!SOURCE] Younger J, Mackey S. "Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study." Pain Medicine, 2009 — Randomized crossover trial demonstrating significant fibromyalgia pain reduction with LDN, establishing the microglial modulation hypothesis for LDN's analgesic mechanism.

[!SOURCE] Younger J et al. "Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels." Arthritis & Rheumatology, 2013 — Follow-up RCT confirming LDN efficacy in fibromyalgia with favorable safety profile, supporting its use in post-traumatic chronic pain syndromes.